Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

BACKGROUND: Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is...

Full description

Bibliographic Details
Main Authors:	Denmeade, SR, Jakobsen, C, Janssen, S, Khan, SR, Garrett, E, Lilja, H, Christensen, S, Isaacs, J
Format:	Journal article
Language:	English
Published:	2003

Similar Items

Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
by: Janssen, S, et al.
Published: (2006)

Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer
by: Emmanuel S. Akinboye, et al.
Published: (2019-01-01)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
by: Janssen, S, et al.
Published: (2004)

Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics
by: John T. Isaacs, et al.
Published: (2021-12-01)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
by: Singh, P, et al.
Published: (2009)

Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer
by: Xinning Wang, et al.
Published: (2021-01-01)

Biology of prostate-specific antigen
by: Lilja, H
Published: (2003)

Biology of prostate-specific antigen.
by: Lilja, H
Published: (2003)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
by: Botchorishvili, G, et al.
Published: (2009)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
by: Haese, A, et al.
Published: (2004)

Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
by: Denmeade, SR, et al.
Published: (2001)

[Isoforms of free prostate-specific antigen]
by: Haese, A, et al.
Published: (2004)

Isoforms of free prostate-specific antigen
by: Haese, A, et al.
Published: (2004)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
by: Evans-Axelsson, S, et al.
Published: (2012)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
by: Vickers, A, et al.
Published: (2011)

Synthesis of the thapsigargins.
by: Ley, S, et al.
Published: (2004)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
by: Alessia Cimadamore, et al.
Published: (2018-12-01)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
by: Vickers, A, et al.
Published: (2009)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

Prostatic specific antigen for prostate cancer detection
by: Lucas Nogueira, et al.
Published: (2009-10-01)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
by: Nouira Yassin, et al.
Published: (2010-12-01)

Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen
by: Michael C. Gong, et al.
Published: (1999-06-01)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
by: Vickers, A, et al.
Published: (2010)

Value of Prostate-Specific Antigen and Prostate-Specific Antigen Density in Detection of Prostate Cancer in an Iranian Population of Men
by: Mahyar Ghafoori, et al.
Published: (2009-08-01)

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
by: Dhar, Shanta, et al.
Published: (2011)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
by: Lilja, H, et al.
Published: (2008)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
by: Cao, Y, et al.
Published: (2002)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
by: Hugosson, J, et al.
Published: (2003)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
by: Törnblom, M, et al.
Published: (2001)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
by: Rien Ritawidya, et al.
Published: (2023-11-01)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
by: Mark Topoozian, et al.
Published: (2023-09-01)

Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer
by: Charles C. Vu, et al.
Published: (2014-01-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)